Sun et al. (2013) have found a significant reduction in the average expression of CTRP9 in both adipocytes and plasma of mice after myocardial infarction. In vivo CTRP9 administration to mice improved their condition by enhancing survival rate and systolic function recovery. Moreover, overexpression of CTRP9 has been shown to alleviate myocardial ischemia-reperfusion injury (IRI) and improve cardiac function (Kambara et al., 2012). It has also been demonstrated that CTRP9 can inhibit superoxide production in diabetes mice (Su et al., 2013). Here, C1QTNF9 is linked to diabetes mellitus.